1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsThis funding opportunity supports projects in accelerator research and development that will advance scientific discovery in nuclear physics research.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Five DOE national laboratories and three universities were selected to lead projects in a previous round. The solicitation is for competitive peer review. Confirm the full requirements in the official notice before applying.
The current listing shows $8.6 million total program funding (Fiscal Year 2022 for new and continuing awards, outyear funding contingent on congressional appropriations). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research and Development (R&D) for Next Generation Nuclear Physics Accelerator Facilities is funded by U.S. Department of Energy (DOE). Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
On September 21, 2026 DOE selected 21 projects under DE-FOA-0003472 — five EGS field tests and 16 exploration wells — for up to $99 million of a $171.5 million authorization. The solicitation is structured to reopen for up to 72 months on roughly annual cycles. Here is how to position for the next one.
Read articleDOE named 31 grid projects across 26 states for $1.9B on September 24, 2026. Recipients bring $3.35B of their own money. Here is what the selection list reveals about how to win the next GRIP round.
Read articleThe DOE Quantum Genesis Q Competition (DE-FOA-0003657) posted September 17, 2026 with an October 19 deadline. Phase I pays $250,000 then $1.25M on milestones; Phase II is a $100M pool plus two $50M bonus pools at 150 and 200 logical qubits. It is an Other Transaction Agreement, not a grant.
Read article